Themis Medicare Q1 FY27 profit turns on ₹100 cr sale

What changed in Q1 FY27

Themis Medicare reported a sharp swing to profit in the first quarter of FY27, but the change was driven by an exceptional gain rather than operating performance. For the quarter ended June 30, 2026, the company posted a standalone net profit (PAT) of ₹2.874 crore, compared with a standalone net loss of ₹1.537 crore in the same quarter last year. On a consolidated basis, profit attributable to equity holders came in at ₹2.461 crore, versus a consolidated loss of ₹1.422 crore in Q1 FY26. Basic EPS for the quarter was reported at ₹3.12, compared with a negative ₹1.67 a year ago.

The one-time exceptional item behind the profit

The profit surge was linked to the sale of shares in an associate company, Gujarat Themis Biosyn Limited. Themis Medicare disclosed it sold 2,497,190 equity shares in the associate for a consideration of ₹100 crore. As a result, it recognised a one-time profit of ₹9.967 crore on a standalone basis and ₹9.295 crore on a consolidated basis.

The company’s disclosure makes it clear that the quarterly profit was not generated by core operations. Excluding the exceptional gain, the standalone operations reported a loss before tax of ₹5.694 crore.

Revenue trend: decline despite profit turnaround

Revenue for the quarter softened even as the headline profitability improved. Standalone revenue stood at ₹8.696 crore, down 10.9% year-on-year from ₹9.758 crore in Q1 FY26. The consolidated revenue was stated to be identical at ₹8.696 crore.

This combination of lower revenue and a profit turnaround is central to understanding the quarter. The reported PAT reflects the impact of the stake sale, while the underlying operating performance, as indicated by the loss before tax excluding the exceptional item, remained weak in the period.

Statutory auditor review and key observations

Krishna & Co., Chartered Accountants, conducted the limited review of the unaudited standalone and consolidated financial results. The auditors stated that nothing came to their attention that would lead them to believe the statements did not comply with the information requirements under Regulation 33 of the SEBI Listing Regulations, or that the statements contained material misstatements.

The limited review report also highlighted a regulatory dependency: pending RBI approval for writing off investments in a struck-off UK subsidiary, Carpo Medicals Limited. The disclosure flags that the write-off is subject to this approval process.

Board meeting and results timeline

A board meeting was scheduled for August 13, 2026 to consider and approve the standalone and consolidated unaudited financial results for the quarter ended June 30, 2026, along with the limited review reports of the statutory auditors. The same communication also stated that the trading window for “Designated Persons” was closed from July 1, 2026 until 48 hours after publication of the financial results.

The text also referenced “Earnings: Expected on 13/08/2026,” aligning with the board meeting date mentioned in the exchange filing.

Stock price references in the text

The data provided included multiple spot price references around mid-August 2026. The Themis Medicare share price was stated as ₹113 as on August 12, 2026 (08:31). Elsewhere, the same input included values of ₹110.05 and an answer line stating the current share price as ₹110.5. These figures appear as separate references within the text.

Snapshot table: Q1 FY27 versus Q1 FY26

Historical quarterly performance cited in the input

The text also included older quarterly performance indicators for the quarter-ended December (Q3 FY25). It reported a 19.7% quarter-on-quarter decrease in consolidated revenues and a 14.1% year-on-year growth for that quarter. Expenses were stated to be down 13.5% QoQ and up 12.9% YoY, while net profit decreased 96.4% QoQ and decreased 92.9% YoY. EPS was cited at 0.1 for Q3 FY25.

In addition, a quarterly results table (figures in ₹ crore) was included for Mar 2025 through Mar 2026. It showed, for example, net sales of ₹97.58 crore in Jun 2025 and profit after tax of -₹15.37 crore for the same quarter, with adjusted EPS of -₹1.67.

Why the quarter matters for investors

The quarter underlines the difference between reported profitability and operating performance. Themis Medicare’s Q1 FY27 profit was materially supported by a one-off exceptional item from an associate stake sale, while revenue declined year-on-year and the underlying standalone result before tax (excluding the exceptional gain) remained negative.

The limited review language is standard for unaudited results, but the mention of pending RBI approval related to the struck-off UK subsidiary is a specific point investors may track for clarity on accounting treatment and timing.

Conclusion

Themis Medicare’s Q1 FY27 results show a headline profit turnaround, primarily due to a ₹100 crore share sale in Gujarat Themis Biosyn and the resulting exceptional gain. The company’s board meeting on August 13, 2026 was scheduled to approve the quarterly results and the auditors’ limited review reports, with the trading window closure tied to the announcement timeline.